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How long has it been since we knew that age-imposed 
changes in the circulatory milieu are to blame for the 
progressive attrition of organs and degenerative 
disorders that invariably accompany human aging? 
Some say, we've known for millennia, from the Ancient 
Greeks and Medieval stories of vampires.  Others say 
that it was McKay’s 1950s experiments, where old rats 
were sutured with young rats to establish parabiosis, 
aka, a joined blood circulation that suggested better 
health of largely non-cellular cartilage [2].  
 
Yet, another answer is that it has been 10 years since the 
paradigm-shifting observations that in heterochronic 
parabiosis, the young systemic milieu rapidly and 
broadly rejuvenates organ stem cells in muscle, 
brain/hippocampus and liver, while the old systemic 
milieu rapidly and broadly ages myogenesis, liver 
regeneration and neurogenesis, with the responsible 
biochemical pathways being re-set to their young or old 
states ([1], and Figure 1).  
 
What paradigms have been shifted? 
 
Before this work, the prevalent theories of tissue decline 
in aging focused on cumulative cell intrinsic changes as 
culprits:   telomere  attrition,   DNA  damage,  oxidative  
 
 

























damage, mitochondrial dysfunction, etc.). While all of 
the above continue to be true for differentiated cells, it 
is important to realize that organ stem cells age 
“extrinsically” [1, 4-7], and maintain a relative “youth” 
that could be due to the state of quiescence, which is 
default for most if not all postnatal stem cells [10]. As 
such, stem cell regenerative capacity persists throughout 
life, but sadly, the biochemical cues regulating organ 
stem cells change with age in ways that preclude 
productive regenerative responses, causing the 
abandonment of tissue maintenance and repair in the old 
[3].  
 
Promisingly, numerous studies have demonstrated that 
experimental youthful re-calibration of specific bio-
chemical cues will quickly (within days) rescue the 
effective regenerative capacity of old stem cells in vivo, 
demonstrating that old stem cells can for all practical 
purposes maintain old organs [4, 11-14]. Such quick 
and robust “rejuvenation” also suggests that not much 
intrinsic “aging” has been experienced by these stem 
cells, or that the intrinsic aging of stem cells can be 
rapidly reversed (within 24 hours) after exposure to 
youthful molecular cues, for example, by activation of 
Notch [4].  Conversely, progeric changes in these 
defined bio-chemical signals make even young stem 
cells behave like old in a day, before the byproducts of 
















pathologies. Many highlighted  recent  reports on  systemic  tissue  rejuvenation  combine parabiosis with a  “silver bullet”
putatively  responsible  for  the  positive  effects.  Attempts  to  unify  these  papers  reflect  the  excitement  about  this
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metabolic stress or environmental damage or prolonged 
entropy could accumulate [3, 5, 7, 14]. 
 
In support of the notion of a maintained, intrinsic 
“youth”, old muscle stem cells do not accumulate DNA 
damage with age [15] and preserve youthful telomerase 
activity [16]. Hence, any new muscle tissue that is 
produced is likely to be healthy. Notably, a genetic 
deficiency in DNA repair doesn’t seem to affect muscle 
regeneration. Indeed, young muscle stem cells from 
SCID mice, which are deficient in non-homologous end 
joining repair, do accumulate more DNA damage than 
wild-type but their muscle regeneration is as effective as 
young wild-type, evidence further uncoupling DNA 
damage from stem cell aging [15].  
 
If all this has been known for 10 years, why is 
there still no therapeutics? 
 
One reason is that instead of reporting broad 


































muscle, liver, and brain by the systemic milieu, the 
impact of the study published in 2005 became narrower. 
The review and editorial process forced the removal of 
the neurogenesis data from the original manuscript. 
Originally, some neurogenesis data were included in the 
manuscript but, while the findings were solid, it would 
require months to years to address the reviewer’s 
comments, and the brain data were removed from the 
2005 paper as an editorial compromise. The 
phenomenon and its magnitude were replicated, 
expanded and elegantly described in a 2011 paper [17]. 
If the friendly neighbor of the Rando lab had not been 
interested in this project after learning of our findings, 
this important result could have been lost or remained 
on a “back-burner” indefinitely. While it is certainly 
better late than never and even if the data are more 
elaborated than in the original manuscript, one can 
argue that the scientific community could already have 
been working on the extrapolation of these results and 
translating them into therapeutics against neuro-









































analysis.  Sections  through  the dentate gyrus of  the hippocampus were  immunostained  for BrdU  (green;  left
panel) or Ki67 (red; right panel) to identify proliferating progenitor cells. Hoechst dye (blue) labels all nuclei. (B)
Quantitation  of  neural  stem  cell  proliferation  as  determined  from  experiments  represented  in  panel  (A).
Counting BrdU+ cells in periodic sections and extrapolating to the entire thickness of the DG estimated the total
number of proliferating neural stem cells. The scales for the young and aged animals are different because of
the marked global  reduction  in neurogenesis  in brains of old mice compared with young mice, as previously
reported. Neural stem cell proliferation was significantly enhanced  for old partners  in heterochronic pairings,
compared to those  in  isochronic pairs  (**p<0.005). There was an  inhibition of proliferation  in young partners
involved in heterochronic pairings compared to those in isochronic pairings (*p<0.05). 
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Another reason for the slow pace in developing 
therapies to broadly combat age-related tissue 
degenerative pathologies is that defined strategies, 
which are “beyond parabiosis”, for the rejuvenation of 
multiple old organs have been very difficult to publish 
in high impact journals; only the magic of 
“heterochronic parabiosis” seems to keep the editors’ 
and reviewers’ attention.  As the result, in the current 
dynamically raging scientific waters, significant work 
that is directly relevant to attenuation or even reversal 
of human tissue aging (e.g., molecules that work in 
mice and are FDA approved or in clinical trials for 
human applications) can sadly get washed over, 
particularly, when relevant publications from lower 
impact journals are not always noticed or cited.  At the 
same time, many highlighted recent reports on systemic 
tissue rejuvenation combine parabiosis with a “silver 
bullet” putatively responsible for the positive effects. 
Attempts to unify these papers (e.g. [18]) reflect the 
excitement about this experimental approach. 
 
What about other potential influences of 
heterochronic parabiosis? 
 
The old parabiont benefits from not just young blood, 
but also the young organs: heart, lungs, liver, kidneys, 
thymus, etc; and removal/neutralization by the young 
parabiont of negative metabolites, chemokines, etc. 
These together with improved blood oxygenation, 
normalized glucose/insulin and cholesterol profile are 
all likely to contribute to the rejuvenated tissue stem 
cells [3, 19]. The young parabiont has to maintain an 
additional aged body with poorly functioning organs, 
inflammation, ongoing pathologies and perturbed 
immune responses, which could all contribute to the 
observed slight decline of the young stem cell 
responses.  
 
The old parabiont has a much more stimulating 
environment when sutured with a young rather than an 
old partner. In contrast to the old and more sedentary 
animals, young mice are active and the old partner 
literally has to tag along. The pheromone landscape also 
becomes changed in hetero-, as compared to isochronic 
pairs. It is known that pheromones as well as 
environmental enrichment enhances, whereas 
environmental deprivation decreases neurogenesis and 
neuronal plasticity [20, 21] and “mock parabioses” have 
not been done to control for this. 
 
Blood cells in parabiotically shared circulation do not 
trans-differentiate to make muscle, brain, etc., tissues 
[22-25]; however, their cytokines certainly influence 
organ stem cell performance [26-28]. Additionally, 
wound clearance by the leukocytes (that becomes 
inefficient with age) is quite important for successful 
regeneration of injured tissues, and tissues of the old 
parabiont would benefit from the young leukocytes 
[29]. 
 
Young and old blood serum and its chemical 
components have inducing/inhibitory properties in 
vitro on stem cells freshly isolated from mice and 
humans [1, 30]. Molecules induced by injury to solid 
tissues “prime” remote organ stem cells in an 
endocrine fashion [31], while stem cell inhibitory 
proteins such as osteopontin become elevated in 
circulation after tissue injury in old mice [12]. Thus, 
some serum-related effects are expected to play a key 
role in stem cell aging and rejuvenation. However, 
these need to be experimentally uncoupled from all the 
other above-mentioned influences in parabiotically 
joined animals.  
 
Is it wise to search mostly for young plasma 
fractions and factors?  
 
One conclusion from the heterochronic parabiosis 
studies is that the regenerative capacity of old tissue 
stem cells can be enhanced by the young systemic 
milieu; however, an over simplistic vision that using 
small volumes of young plasma or a “systemic silver 
bullet” will provide rejuvenation, e.g. one circulating 
molecule, at this point seems unlikely.  Aging is a 
multi-genic process, the list of potential “silver bullets” 
is short, and some are oncogenic.  Notably, while 
administration of small volume of young plasma to aged 
mice improved their cognition, the effects on brain or 
other tissue stem cells or health span have not been 
studied [32]. Most importantly, the positive effects of 
young blood on old are only partial for muscle and the 
increase neurogenesis is nowhere near levels seen in 
young brain (Figure 1, [1, 17, 32, 33]). Moreover the 
strong inhibition of young tissue stem cells by the aged 
systemic milieu in vivo and by old serum in vitro have 
been repeatedly reported [3, 34-36].  Summing up what 
is known, introducing small volumes of young plasma 
into an old host may not work effectively for enhancing 
tissue regeneration in the old, unless the inhibitory 
components of the aged circulation are neutralized or 
removed. And notably, removal or neutralization of 
these inhibitory systemic factors is predicted to have a 
positive effect on tissue repair by itself [6, 11, 19, 37]. 
  
Additionally, it is not clear which levels of the 
circulatory molecule(s) are necessary and sufficient for 
the pro-regenerative activity of the old stem cells.  
Many factors, such as TGF-beta1, Wnt, or pp38α 
become inhibitory at the excessive levels seen with age 
but are needed for normal cell and tissue homeostasis at 
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their young levels and furthermore, are biphasic 
during the regenerative process (Figure 2 and [3, 30, 
37-39]).  
 
GDF11 abdicates the throne of systemic 
rejuvenation 
 
As recently revealed, the key findings on diminished 
levels of GDF11 with age and of the positive effects of 
this protein on myogenesis are not reproduced [36, 40-
42].  Very importantly, this would not come as a shock 
if one would read the relevant papers. Based on the 
science, GDF11 is 90% identical to myostatin, which 
inhibits (not activates) myogenesis. GDF11 in 
neurogenesis serves to limit the numbers of neural stem 
cells [43, 44] and this discrepancy was not cited or 
discussed in the pro-rejuvenation papers.  GDF11 
signals through the same receptor as TGF-beta1 and 
myostatin (more efficiently than myostatin [40] and 
inhibition (not activation) of this ALK5 receptor has 
been shown to enhance and rejuvenate myogenesis and 
also, neurogenesis [6, 37]. The bulk of data questions 
the anti-aging effects of GDF11, and makes the Cell 
Metabolism paper important for avoiding years of 
unproductive research in the wrong directions. 
 




























attenuating the accumulation of DNA damage in the 
aged satellite cells [36]; however, a year earlier it was 
published that old muscle satellite cells do not 
accumulate DNA damage with age and that DNA 
damage in muscle stem cells is uncoupled from 
efficiency of muscle repair and likely represents a 
physiologically required process of terminal myogenic 
lineage differentiation [15], [45]. Once again, a key 
paper in a lesser impact journal questioning main 
conclusions of a high impact paper was not cited or 
caught in peer or editorial review. 
 
In apparent disagreement between two recent studies, 
GDF11 does [41] and does not [46] reduce hypertrophy 
of old mouse hearts.  Even if there is no direct 
connection to aging, stem cells or heterochronic 
parabiosis, ectopic GDF11 may reduce the mass of both 
young and old hearts [47].  
 
Age-specific levels of GDF11 are also not without 
controversy: initially, it was reported that GDF11, but 
not GDF8/myostatin, declines with age [41]; then more 
recently it was determined that GDF8/myostatin does 
decline with age [48], an observation which was also 
reconfirmed by the original Cell authors, who now 
combine the two protein names into one, called 
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Figure  2.  Bi‐phasic  requirements  for  TGFβ,  myostatin,  pp38,  Wnt  during  muscle  repair.




mitotic multi‐nucleated myotubes.  In vitro,  intermediate progenitors  can be expanded  in high mitogen
medium and upon withdrawal of mitogens they form multi‐nucleated myotubes in culture. 
 
These controversies may be caused by the fact that 
antibodies to GDF11 have cross-reactivity with 
GDF8/myostatin.  GDF11 antibody might also simply 
cross-react with immunoglobulins, which become 
elevated with age [47, 49].  A very elegant recent paper 
using a clean myostatin knock-out system demonstrated 
that GDF11 levels are 500 times less than that of 
myostatin or activin, thus precluding any competitiveness 
for the same receptor complexes and arguing against 
physiological modulation of pSmad2/3 signaling by 
GDF11 when myostatin, activin or TGF- beta1 are 
present [48]. 
 
Muscle tissue produces myostatin, so the age-specific 
decline in myostatin protein may reflect the loss of 
muscle mass in the old. Consequentially people or mice 
with physiologically higher muscle mass (particularly in 
older age) are likely to be healthier, thus exhibiting an 
indirect link between the levels of myostatin and the 
health of the heart and other organs. Notably, GDF11 is 
associated with human colon cancers, which is likely 
due to the pro-angiogenic properties of GDF11 and 
most TGF-beta family ligands [50, 51]. Accordingly, 
Alk1 and Alk5 inhibitors are studied as anti-cancer anti-
angiogenic blockers [52, 53]. 
 
Extrinsic versus intrinsic is semantics 
 
If p38 becomes up regulated or telomere maintenance 
inhibited in cells with age, because TGF-beta in their 
environment becomes elevated, should this be 
considered intrinsic or extrinsic aging [54]? 
Accordingly, if either inhibition of p38 or of TGF-beta 
signaling improves myogenicity, was the intrinsic or 
extrinsic aging reversed? A number of recent papers 
[14, 55-57] reveal persistent age-specific changes in 
muscle stem cells, but the data shown in these 
manuscripts does not directly dispute the original 
findings that in hetero-chronic muscle transplants both 
young and old cells do worse in the old host than in 
young [58]. Moreover, in the intrinsic-focused papers 
the regenerative capacity of the aged stem cells is 
quickly enhanced, for example, by changes in 
phosphorylation of intracellular proteins meaning that 
such “aging” is acutely reversible, in agreement with 
heterochronic parabioses. Even with respect to the 
induction of p16 and of muscle stem cell senescence 
with advancing age, experimental recovery into more 
youthful phenotypes have been reported, albeit it 
remains to be seen if there is a dilution of irreversibly 
senescent cells by the boost of pre-senescent cell 
proliferation, or a bone fide reversion of the senescence 
program in cells [57, 59, 60].  
 
 
Namely, inhibitors of p38, a determinant that restricts 
proliferation and promotes differentiation of muscle 
progenitors [61] enhanced the transplantation efficiency 
of old myogenic cells [55, 59]. p38 α, β, γ and δ isoforms 
are differentially expressed in various cells [61, 62] and 
interestingly, unlike the isoform α, p38 β or γ KO did not 
alter adult myogenesis [63]. Significant recent work 
established conservation in the regulatory myogenic 
activity of p38 between mouse and human muscle stem 
cells [64].  p38 levels are perturbed in the old and 
pathological cells due to a number of extrinsic and 
intrinsic cues, including the ROS-related DNA damage 
and perturbed mitochondrial activity;  and p38 inhibitors 
have been hence, examined for many years [65-69].  
 
It is well known that the intracellular changes (be those 
in phosphorylation status of proteins, gene expression or 
epigenome) are regulated by the signals emanating from 
stem cell niches and that such signals change with age 
in ways that inhibit engagement of stem cells in tissue 
maintenance and repair. The regulation of stem cell 
homeostasis by differentiated niches is evolutionary 
conserved between such distinct species as flies, mice 
and humans [3, 70-72]. The semantics of intrinsic 
(autonomous) versus extrinsic aging of stem cells is 
illustrated in Figure 3.  
 
Even for the stronghold of “autonomous aging”, 
hematopoietic stem cells (HSCs) [73, 74], a 
combination of both intrinsic and extrinsic age-related 
changes seems to be in place [75, 76]. In addition to wet 
lab studies, the age-imposed extrinsic influences on 
HCSs have been modeled mathematically [77, 78].  The 
relative contribution of niche-directed versus intrinsic 
aging may, of course, differ in different regenerative 
cells: for example, the levels of aberrantly processed 
Lamin A (progerin) increase with age in bone marrow 
adult multilineage cells (also known as mesenchymal 
stem cells) where experimental induction of progerin in 
young cells, significantly disrupts the expression and 
localization of self-renewal markers and the 
regenerative capacity of cells, in part through 
deregulation of Oct1, and subsequent perturbation of the 
mTor pathway and autophagy [79, 80]. 
 
On a related note, while a consensus has not yet been 
reached on whether and to what degree muscle stem cells 
are lost with age, and if these cells are exhausted via 
proliferation or in contrast, up regulate CDK inhibitors, 
keep their loci epigenetically open and fail to proliferate 
[15, 55, 60, 81, 82], there is general agreement that 
regeneration and maintenance of multiple organs can be 
enhanced in old mammals by boosting performance of 
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their own aged stem cells, without ectopic gene 
expression or cell transplantation [3, 10, 14, 42].  
 
In the same vein, mature myofibers are known to 
synthesize protein and increase in size by hypertrophy 
[83], which still occurs when 85-90 % of satellite cells 
are ablated [81]. Despite semantics, this does not 
exclude contribution of muscle stem cells to this tissue 
even in sedentary mice [84] or the effects of their 
functional decline with aging particularly when muscle 
needs rebuilding upon exercise or attrition [85, 86].  
 
Some current stem cell-focused approaches attempt to 
circumvent the niche aging by normalizing stem cell 
regulatory signaling to its “youthful intensity” (Figures 3  
and 4; as discussed below).  The exciting possibility 
exists that boosting stem cell responses simultaneously in 
multiple tissues will actually rejuvenate the differentiated 
cells, such that over time less and less intervention will 
be needed and the intrinsic age-imposed changes in the 
differentiated soma would be broadly attenuated or 


































nerative capacity of old tissue stem cells is unrelated to 
and despite the phenomenon of reduced functionality of 
induced pluripotent stem cells (iPSCs) that are derived 
from aged somatic cells (usually fibroblasts) [87], 
although it would be interesting to examine if 
differentiated tissue cells derived from rejuvenated old 
stem cells now have the same functionality as those 




There is a lot of interest and excitement in the field of 
aging research and clinical translation is highly 
anticipated. Even better news is that we do not have to 
start from scratch and embark on serum or plasma 
fractionation. Instead, based on published work, 
agonists and antagonists of specific signaling pathways 
(some already developed and some FDA approved or in 
clinical trials), could be used systemically to quickly re-
set tissue stem cells residing in old organs to their 
“young” robust regenerative capacity, e.g. overriding 
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Figure 3. Intrinsic / extrinsic aging of tissue stem cells. Based on the body of published
literature,  gene  expression,  epigenome,  signal  transduction  and  behavior  of  stem  cells  are
influenced  by  the  signals  that  emanate  from  their  local  and  systemic  niches.  Niche  cells
experience intrinsic aging, which results in the changed extrinsic influences on tissue stem cells.






















































As a proof of principle, this approach has worked for 
rejuvenation of myogenesis by activation of Notch or 
MAPK pathways, by attenuation of Jak/Stat signaling, 




















































These and other cell-fate regulatory pathways are highly 
interactive and some of their interesting and age-res-
ponsive cross talks have been revealed [3, 30, 60, 90, 
91]. 
Figure 4. Key regulatory signaling pathways that become deregulated with age. The interactive developmentally and evolutionary
conserved Notch,  TGF‐beta/BMP,  Jak/Stat, p38, oxytocin/MAPK,  and mTOR  signaling pathways  control  function of  tissue  stem  cells  and
change with age in ways that interfere with tissue maintenance and repair. Experimental modulation of these pathways enhanced the tissue
regenerative capacity  in old mammals. Beginning clockwise  from  top  left.   TGFβ and BMP pathway  increase with age and activate pp38,
transient  inhibition of which  is sufficient  to  restore myogenic potential  in muscle stem cells.   TGFβ and BMP also separately act  through
SMADs,  inhibiting these SMADs was also found to rescue from some of the negative effects of these pathways pathogenic activation with
age. JAK/STAT is a cytokine receptor pathway that increases with age. Many inflammatory cytokines act through this pathway. Inhibition of
this pathway  restores muscle satellite cell symmetric expansion. Delta/Notch signaling decreases with age,  the activation of which  in old
muscle restores its regenerative potential.  Oxytocin signaling decreases with age, restoring this signaling improves aged muscle satellite cell
function.  These  intracellular  signaling  pathways  are  highly  interactive.  TGFβ  acts  through  SMADs  to  influence  downstream  cytokine
production which act on the Jak/Stat pathway, and SMAD3 and the Notch Intracellular Domain (NICD) interact directly to form a complex
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Simultaneous rejuvenation of myogenesis and hippo-
campal neurogenesis and reduction of inflammation 
(Beta 2 Microglobulin, B2M levels) in the same old 
animal have been achieved by one systemically applied 
TGF-beta receptor inhibitor, and confirmed by genetic 
approaches [6]. Heterochronic parabiosis also reduced 
the age-elevated B2M [92].  Down-modulation of BMP 
signaling enhanced hippocampal neurogenesis in old 
mice [93], and neutralization of TGF-beta signaling 
rejuvenated olfactory bulb neurogenesis [94].  A recent 
study suggests that age-imposed elevation in Smad4 (via 
deregulation of miR-431) as a mechanism by which both 
TGF-beta and BMP signaling branches become elevated 
with age [95]. 
 
Similar attenuation of TGF-beta receptor signaling by 
systemically administered small molecule has greatly 
improved muscle regeneration at the onset of full 
diabetes, where muscle stem cell responses are blocked 
by an upregulation of myostatin [19]. Interestingly, this 
class of TGF-beta receptor inhibitors is in clinical trials 
for  combating  solid  tumors   (https://clinicaltrials.gov/ 
ct2/results?term=alk5&Search=Search, NCT02160106). 
TGF-beta signaling activates the p38 pathway, hence 
Alk5 inhibitors also promise to normalize the elevated, 
pathological levels of pp38 [96, 97].  Thus multiple 
positive effects can be expected, particularly in the old.  
 
In addition to the changes in the biochemical cues from 
local and systemic niches or possibly due to these 
changes, some stem cells become less sensitive to 
activating stimuli with age, which might be due to the 
elevated activity of the molecular target of rapamycin, 
mTOR pathway [98].  Attenuation of mTOR with 
rapamycin is being explored as a multi-faceted anti-
aging strategy for combatting senescence-associated 
permanent cell cycle arrest [99, 100] and enhancing 
tissue regeneration, and rapamycin was suggested to 
promote stem cell responses [98] and even increase life 
span in mice [101].  
 
Exploring the secretome of hESCs as a more convenient 
and translational approach than young blood, a key age- 
specific role of MAPK has been uncovered; and several 
novel FGFs have been identified for their pro-
regenerative activity on old tissue stem cells in part, by 
activating the Delta/Notch pathway, and this is 
conserved between mice and humans [13, 89]. The 
hESC-secreted pro-regenerative proteins can be isolated 
via heparin affinity; they enhance regenerative capacity 
of muscle and neuronal stem cells and are neuroprotec- 
tive in an in vitro model of Alzeimer’s disease [13, 89]. 
A search for the physiologic MAPK agonist that has 
receptors on muscle stem cells and declines in 
circulation with aging has identified the FDA approved 
small peptide oxytocin as a novel anti-aging 
systemically acting molecule with positive effects on 
skeletal muscle and bone, mental well being and 
combating obesity [5, 7, 102-105]. 
 
Attenuating inflammatory chemokines and cytokines, 
including those produced at high levels by senescent 
cells (SASP), and ablating senescent cells (for example, 
via the use of their cell-surface markers) are expected to 
enhance tissue maintenance and regeneration, as well as 
diminish the risk of the age-related flare of cancers. In 
this regard, excellent mouse models reporting 
senescence in vivo and enabling selective ablation of 
p16high cells in live animals have been recently 
described [106, 107].   
 
These reports demonstrate rational strategies to 
attenuate and possibly reverse multi-tissue attrition, 
preventing a number of degenerative and metabolic 
diseases (sarcopenia, osteoporosis, obesity, diabetes, 
neuro-degeneration, etc.) as a class, instead of or in 
addition to approaching each disease individually, 
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